clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Katayama M et al. Preliminary study of effects of multiple oral dosing of clarithromycin on the pharmacokinetics of cyclosporine in dogs. 2014 J. Vet. Med. Sci. pmid:24189617
Papastergiou V et al. Current and future insights in H. pylori eradication regimens: the need of tailoring therapy. 2014 Curr. Pharm. Des. pmid:24180408
Tan X and Song Z Human saliva-based quantitative monitoring of clarithromycin by flow injection chemiluminescence analysis: a pharmacokinetic study. 2014 Appl. Biochem. Biotechnol. pmid:24166104
Kakuda TN et al. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. 2014 J. Antimicrob. Chemother. pmid:24155058
Kathariya R et al. Evaluation of subgingivally delivered 0.5% clarithromycin as an adjunct to nonsurgical mechanotherapy in the management of chronic periodontitis: a short-term double blinded randomized control trial. 2014 J Investig Clin Dent pmid:23097216
Shahbazi Niaz M et al. Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. 2014 Pharm Dev Technol pmid:24093825
Maev IV et al. [Eradication therapy for Helicobacter pylori infection: review of world trends]. 2014 Ter. Arkh. pmid:24779078
Katagiri S et al. [Case report; Disseminated Mycobacterium abscessus infection with hemophagocytic syndrome during treatment of chronic lymphocytic leukemia]. 2014 Nippon Naika Gakkai Zasshi pmid:24796145
Tsovolou EC et al. Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa. 2014 APMIS pmid:23656439
Altman E et al. Lipopolysaccharide glycotyping of clarithromycin-resistant and clarithromycin-susceptible Canadian isolates of Helicobacter pylori. 2014 Can. J. Microbiol. pmid:24392924
Yamada K et al. Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells. 2014 Pulm Pharmacol Ther pmid:24910464
Page SR and Yee KC Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. 2014 Intern Med J pmid:25041770
El-Garem Y et al. Seminal Helicobacter pylori treatment improves sperm motility in infertile asthenozoospermic men. 2014 Urology pmid:25432826
Matongo F and Nwodo UU In vitro assessment of Helicobacter pylori ureases inhibition by honey fractions. 2014 Arch. Med. Res. pmid:25240315
Martos M et al. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. 2014 Eur J Gastroenterol Hepatol pmid:25229983
Veraldi S et al. Treatment of sporotrichoid fish tank granuloma with pulsed clarithromycin. 2014 Dermatology (Basel) pmid:25228273
Phillips RO et al. Reply to "compliance with antimicrobial therapy for buruli ulcer". 2014 Antimicrob. Agents Chemother. pmid:25225343
Patel SK et al. Helicobacter pylori is not eradicated after triple therapy: a nested PCR based study. 2014 Biomed Res Int pmid:25054141
Elkhatib W and Noreddin A Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model. 2014 Microb. Drug Resist. pmid:25050970
Ohe M and Bohgaki T Successful treatment with clarithromycin for patients with polymyalgia rheumatica. 2014 Korean J. Intern. Med. pmid:25045305
Dalbøge CS et al. Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. 2014 J. Cyst. Fibros. pmid:24035278
Sugimoto M and Furuta T Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. 2014 World J. Gastroenterol. pmid:24914361
Heo J and Jeon SW Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. 2014 World J. Gastroenterol. pmid:24914324
Glatz M and Muellegger RR Drug-associated aquagenic wrinkling of the palms in an atopic male patient. 2014 BMJ Case Rep pmid:24903725
DiCicco M et al. In vitro synergism of fosfomycin and clarithromycin antimicrobials against methicillin-resistant Staphylococcus pseudintermedius. 2014 BMC Microbiol. pmid:24886369
Noonan KA et al. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. 2014 Cancer Immunol Res pmid:24878583
Ikawa K et al. Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages. 2014 J Clin Pharm Ther pmid:24661290
Varvyanskaya A and Lopatin A Efficacy of long-term low-dose macrolide therapy in preventing early recurrence of nasal polyps after endoscopic sinus surgery. 2014 Int Forum Allergy Rhinol pmid:24659566
Lee SH et al. Detection and assessment of clarithromycin inducible resistant strains among Korean Mycobacterium abscessus clinical strains: PCR methods. 2014 J. Clin. Lab. Anal. pmid:24652818
Binh TT et al. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. 2014 J. Antimicrob. Chemother. pmid:24648504
Tursi A et al. Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study. 2014 Panminerva Med pmid:24637473
Wei Z et al. Rome III criteria cannot distinguish patients with chronic gastritis from those functional dyspepsia patients. 2014 Helicobacter pmid:24617669
Rizzo A et al. Antimicrobial effect of natural polyphenols with or without antibiotics on Chlamydia pneumoniae infection in vitro. 2014 Microb. Drug Resist. pmid:23952319
Zhang J et al. Ocular penetration and pharmacokinetics of topical clarithromycin eye drops to rabbits. 2014 J Ocul Pharmacol Ther pmid:24199739
Ali Habib HS et al. Effect of sequential versus standard Helicobacter pylori eradication therapy on the associated iron deficiency anemia in children. 2013 Sep-Oct Indian J Pharmacol pmid:24130381
Mégraud F Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. 2013 Nov-Dec Gut Microbes pmid:23929066
Suzaki I et al. Enhancement of thioredoxin production from nasal epithelial cells by the macrolide antibiotic, clarithromycin in vitro. 2013 May-Jun In Vivo pmid:23606690
Dajani AI et al. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? 2013 May-Jun Saudi J Gastroenterol pmid:23680708
Petitto J et al. Successful clarithromycin desensitization in a macrolide-sensitive pediatric patient. 2013 May-Jun J Allergy Clin Immunol Pract pmid:24565493
Cottle LE et al. A multinational outbreak of histoplasmosis following a biology field trip in the Ugandan rainforest. 2013 Mar-Apr J Travel Med pmid:23464714
Molina-Infante J and Gisbert JP [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. 2013 Jun-Jul Gastroenterol Hepatol pmid:23623461
Razafimahefa SH et al. [Helicobacter pylori: what eradication regimen in a tropical area after the failure of two separate lines of eradication including metronidazole and clarithromycin?]. 2013 Jan-Mar Med Sante Trop pmid:23360589
Mandras N et al. Antibacterial efficacy and drug-induced tooth discolouration of antibiotic combinations for endodontic regenerative procedures. 2013 Apr-Jun Int J Immunopathol Pharmacol pmid:23755774
Srivastava S et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? 2013 Eur. Respir. J. pmid:24293417
Yakoob J et al. Low rate of recurrence of Helicobacter pylori infection in spite of high clarithromycin resistance in Pakistan. 2013 BMC Gastroenterol pmid:23433429
Amin M et al. Anti-Helicobacter pylori and urease inhibition activities of some traditional medicinal plants. 2013 Molecules pmid:23434867
Kato H et al. Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide. 2013 Ann. Hematol. pmid:23625297
Togami K et al. Subcellular distribution of azithromycin and clarithromycin in rat alveolar macrophages (NR8383) in vitro. 2013 Biol. Pharm. Bull. pmid:23995662
Kim SG et al. Helicobacter pylori eradication on iatrogenic ulcer by endoscopic resection of gastric tumour: a prospective, randomized, placebo-controlled multi-centre trial. 2013 Dig Liver Dis pmid:23333104
Feng Z et al. Dissociative disorder induced by clarithromycin combined with rabeprazole in a patient with gastritis. 2013 J. Int. Med. Res. pmid:23569151